Vascular Solutions Preparing For Duett Vascular Sealing Launch, Going Public
This article was originally published in The Gray Sheet
Executive Summary
Vascular Solutions says it will allocate roughly $12 mil. of its upcoming $40 mil. initial public offering to establish a direct U.S. sales force over the next year to market the Duett vascular sealing device, which currently awaits FDA approval.
You may also be interested in...
Datascope v. Vascular Solutions
Motion for summary judgement by Vascular Solutions is granted March 15, thereby dismissing all counts of the patent infringement complaint brought by Datascope in July 1999 in U.S. district court. Datascope's complaint alleged that the clinical studies of the Vascular Solutions Duett sealing device infringed patents held by Datascope. The summary judgement is subject to appeal. The Duett, Vascular Solutions' only product, is awaiting FDA approval (1"The Gray Sheet" Aug. 9, p. 14)
Datascope v. Vascular Solutions
Motion for summary judgement by Vascular Solutions is granted March 15, thereby dismissing all counts of the patent infringement complaint brought by Datascope in July 1999 in U.S. district court. Datascope's complaint alleged that the clinical studies of the Vascular Solutions Duett sealing device infringed patents held by Datascope. The summary judgement is subject to appeal. The Duett, Vascular Solutions' only product, is awaiting FDA approval (1"The Gray Sheet" Aug. 9, p. 14)
Vascular Solutions' Duett Reduces Time To Hemostasis - Final SEAL Data
Time to hemostasis during interventional procedures was "significantly and noticeably decreased" using Vascular Solutions' Duett femoral closure device compared to manual compression, Stephen Ellis, MD, Cleveland Clinic, told attendees of the American Heart Association's scientific sessions Nov. 9 in Atlanta.